Liver Meeting 2018 conference is this week in San Francisco. This Vanco article below is also from Stanford U related people, but this may involve other patients too (other than phase3 trial).
“Long-Term Treatment with Oral Vancomycin for the Treatment of Primary Sclerosing Cholangitis and Inflammatory Bowel Disease”
“Methods: Pediatric and adult patients with PSC at two major medical centers were treated with OV over a 15-year period. Clinical symptoms, laboratory values, radiological studies, and liver biopsies were documented for 12 months after initiation of OV.”
" Results: A total of 59 subjects (64% male) with a median age of 13.5 years (1.5 - 44) at diagnosis were enrolled. Forty-five patients were pediatric patients (<18 years). Ninety-four percent had concomitant IBD (92% UC, 8% Crohn’s disease). Patients received OV at a dose of 50 mg/kg/day divided 3 times per day if weight < 30 kg and 500 mg 3 times per day if ≥ 30 kg. Patients were treated for a median of 2.9 years. Forty four percent had normalization of GGT, 59% had normalization of ALT, and 20% had normalization of ALP. All patients had a reduction in ALT, and 91.5% had a reduction in GGT. Seventy-six percent had follow-up MRI while on OV, and all patients had either stable or improved hepatic stricture, periductal inflammation, biliary dilatation, and/or fibrosis. Twenty-eight patients had liver biopsy post-OV treatment, and all had either stable disease or improvement in inflammation. Sixty-nine percent of patients had improvement in abdominal pain and diarrhea related to IBD. No subjects developed hepatobiliary or colorectal cancer. One patient had a liver transplant 8 years after starting vancomycin treatment, however he had advanced cirrhosis at time of initiation of vancomycin. None of the patients developed side effects. There was no significant difference in response to vancomycin for age, sex, severity of liver fibrosis, and small compared to large duct disease.
Conclusion: The long-term use of OV in PSC is associated with improvement in liver biochemistries and stabilization or improvement in histological and cholangiographic abnormalities."
https://plan.core-apps.com/tristar_aasld18/abstract/3b9b2f3af8aefb4e9fba71511db0fb86